Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Transarterial Chemoembolization With or Without Sorafenib for Patients With Hepatocellular Carcinoma and Microvascular Invasion

NCT02436902 is registered in ClinicalTrials.gov with Guangxi Medical University as lead sponsor.

NCT NCT02436902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02436902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Transarterial Chemoembolization With or Without Sorafenib for Patients With Hepatocellular Carcinoma and Microvascular Invasion
Lead sponsor
Guangxi Medical University
Phase
Phase 3
Overall status
Unknown status
Start date
February 1, 2019
Completion date
August 30, 2022
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma